Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03329092
Previous Study | Return to List | Next Study

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. (REVISIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03329092
Recruitment Status : Suspended (Recruitment has been suspended in study C3601002 due to a delay in investigational product availability)
First Posted : November 1, 2017
Last Update Posted : June 17, 2019
Sponsor:
Collaborators:
Innovative Medicines Initiative (IMI) COMBACTE-CARE (EU)
Biomedical Advanced Research and Development Authority
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE October 6, 2017
First Posted Date  ICMJE November 1, 2017
Last Update Posted Date June 17, 2019
Actual Study Start Date  ICMJE April 5, 2018
Estimated Primary Completion Date September 8, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 27, 2017)
Proportion of subjects with clinical cure in the ITT and CE analysis sets [ Time Frame: Test of Cure (TOC) visit, Day 28 +/- 3 days ]
Proportion of subjects meeting the criteria for clinical cure
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03329092 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 27, 2017)
  • Proportion of subjects with clinical cure in the m-ITT and ME analysis sets [ Time Frame: Test of Cure (TOC) visit, Day 28 (+/- 3 days) ]
    Proportion of subjects meeting the criteria for clinical cure
  • Proportion of subjects with clinical cure by infection type in the ITT and CE analysis sets. [ Time Frame: Test of Cure (TOC) visit, Day 28 (+/- 3 days) ]
    Proportion of subjects meeting the criteria for clinical cure
  • Proportion of subjects with clinical cure for subjects with MBL positive pathogens in the micro ITT and ME analysis sets. [ Time Frame: Test of Cure (TOC) visit, Day 28 (+/- 3 days) ]
    Proportion of subjects meeting the criteria for clinical cure
  • Proportion of subjects with a favorable per subject microbiological response in the micro ITT and ME analysis sets. [ Time Frame: Test of Cure (TOC) visit, Day 28 (+/- 3 days) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication + presumed eradication)
  • Proportion of subjects who died [ Time Frame: Day 28 ]
    Daily mortality assessment
  • PK of ATM [ Time Frame: Days 1 and 4 ]
    Plasma concentration of ATM
  • PK/PD relationship between exposure and clinical response for ATM AVI±MTZ in the popPK analysis set [ Time Frame: Test of Cure (TOC) visit, Day 28 (+/- 3 days) ]
    Correlation between plasma concentration of ATM and clinical cure
  • PK of AVI [ Time Frame: Days 1 and 4 ]
    Plasma concentration of AVI
  • PK/PD relationship between exposure and clinical response for ATM/AVI +/- MTZ in the popPK analysis set [ Time Frame: Test of Cure (TOC) days 28 (+/- 3 days) ]
    Correlation between concentration of AVI and clinical cure
  • PK/PD relationship between exposure and microbiological response for ATM/AVI+/-MTZ in the popPK analysis set [ Time Frame: Test of Cure (TOC) visit, Days 28 (+/- 3 days) ]
    Correlation between plasma concentration of ATM and microbiological response
  • PK/PD relationship between exposure and microbiological response for ATM/AVI+/-MTZ in the popPK analysis set [ Time Frame: Test of Cure (TOC) visit, day 28 (+/- 3 days) ]
    Correlation between plasma concentration of AVI and microbiological response
  • Description of safety in terms of adverse events [ Time Frame: Throughout study to Late Follow Up visit (Day 45 +/- 3 days) ]
    Descriptive summary of adverse events
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: November 16, 2017)
  • Proportion of subjects with clinical cure in the ITT, micro ITT, CE and ME analysis sets [ Time Frame: End of Treatment (EOT) visit (variable, between Days 1 and 15) ]
    Proportion of subjects meeting the criteria for clinical cure
  • Proportion of subjects with clinical cure by infection type in the ITT and CE analysis sets [ Time Frame: End of Treatment (EOT) visit (variable, between Days 1 and 15) ]
    Proportion of subjects meeting the criteria for clinical cure
  • Proportion of subjects with a favorable per subject microbiological response in the the micro ITT and ME analysis sets [ Time Frame: End of Treatment (EOT) visit (variable, between Days 1 and 15) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with a favorable per pathogen microbiological response in the micro ITT and ME analysis sets [ Time Frame: End of Treatment (EOT), (variable between Days 1 and 15) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with a favorable per subject microbiological response by pathogen resistance type (eg, ATM resistant, ESBL positive, carbapenamase positive, MBL positive) in the micro ITT and ME analysis sets [ Time Frame: End of Treatment (EOT), (variable, between Days 1 and 15) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with a favorable per pathogen microbiological response by pathogen resistance type in the micro ITT and ME analysis sets [ Time Frame: End of Treatment (EOT) visits, (variable between Days 1 and 15) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with clinical cure using objective clinical measures [ Time Frame: Test of Cure (TOC) visit, Day 28 +/- 3 days) ]
    Proportion of subjects with clinical cure
  • Proportion of subjects who died [ Time Frame: Day 14 ]
    Daily mortality assessment
  • Health resource utilization in terms of length of hospital stay [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Length of hospital stay (days), including any readmissions
  • Relationship between (as yet undetermined) biomarkers and liver transaminase elevations in response to exposure to ATM-AVI [ Time Frame: Day 1 and 4 ]
    Correlation between (yet to be determined) plasma biomarkers and elevated liver transaminases
  • Proportion of subjects with a favorable per pathogen microbiological response in the micro ITT and ME analysis sets [ Time Frame: Test of Cure (TOC) visit (Day 28 +/- 3 days) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with a favorable per subject microbiological response by pathogen resistance type (eg, ATM resistant, ESBL positive, carbapenamase positive, MBL positive) in the micro ITT and ME analysis sets [ Time Frame: Test of Cure (TOC) visits, Day 28 +/- 3 days ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with a favorable per pathogen microbiological response by pathogen resistance type in the micro ITT and ME analysis sets [ Time Frame: Test of Cure (TOC) visits, Day 28 +/- 3 days ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Health resource utilization in terms of treatment duration [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Length of study treatment (days)
  • Health resource utilization in terms of length of ICU stay [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Length of intensive care unit (ICU) stay (days)
  • Health resource utilization in terms of transfer to ICU [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Transfer to the ICU (Yes/No)
  • Health resource utilization in terms of use of mechanical ventilation [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Mechanical ventilation (Yes/No) for HAP/VAP subjects
  • Health resource utilization in terms of duration of mechanical ventilation [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Length of mechanical ventilation (days) for HAP/VAP subjects
  • Health resource utilization in terms of subsequent unplanned surgical intervention [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Subsequent unplanned surgical intervention (YES/NO) for cIAI subjects
Original Other Pre-specified Outcome Measures
 (submitted: October 27, 2017)
  • Proportion of subjects with clinical cure in the ITT, micro ITT, CE and ME analysis sets [ Time Frame: End of Treatment (EOT) visit (variable, between Days 1 and 15) ]
    Proportion of subjects meeting the criteria for clinical cure
  • Proportion of subjects with clinical cure by infection type in the ITT and CE analysis sets [ Time Frame: End of Treatment (EOT) visit (variable, between Days 1 and 15) ]
    Proportion of subjects meeting the criteria for clinical cure
  • Proportion of subjects with a favorable per subject microbiological response in the the micro ITT and ME analysis sets [ Time Frame: End of Treatment (EOT) visit (variable, between Days 1 and 15) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with a favorable per pathogen microbiological response in the micro ITT and ME analysis sets [ Time Frame: End of Treatment (EOT), (variable between Days 1 and 15) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with a favorable per subject microbiological response by pathogen resistance type (eg, ATM resistant, ESBL positive, carbapenamase positive, MBL positive) in the micro ITT and ME analysis sets [ Time Frame: End of Treatment (EOT), (variable, between Days 1 and 15) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with a favorable per pathogen microbiological response by pathogen resistance type in the micro ITT and ME analysis sets [ Time Frame: End of Treatment (EOT) visits, (variable between Days 1 and 15) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with clinical cure using objective clinical measures [ Time Frame: Test of Cure (TOC) visit, Day 28 +/- 3 days) ]
    Proportion of subjects with clinical cure
  • Proportion of subjects who died [ Time Frame: Day 14 ]
    Daily mortality assessment
  • Health resource utilization in terms of length of hospital stay [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Length of hospital stay (days), including any readmissions
  • Relationship between (as yet undetermined) biomarkers and liver transaminase elevations in response to exposure to ATM-AVI [ Time Frame: Day 1 and 4 ]
    Correlation between (yet to be determined) plasma biomarkers and elevated liver transaminases
  • Proportion of subjects with a favorable per pathogen microbiological response in the micro ITT and ME analysis sets [ Time Frame: Test of Cure (TOC) visit (Day 28 +/- 3 days) ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with a favorable per subject microbiological response by pathogen resistance type (eg, ATM resistant, ESBL positive, carbapenamase positive, MBL positive) in the micro ITT and ME analysis sets [ Time Frame: Test of Cure (TOC) visits, Day 28 +/- 3 days ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Proportion of subjects with a favorable per pathogen microbiological response by pathogen resistance type in the micro ITT and ME analysis sets [ Time Frame: Test of Cure (TOC) visits ]
    Proportion of subjects with a favourable microbiological response (aggregate of eradication and presumed eradication)
  • Health resource utilization in terms of treatment duration [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Length of study treatment (days)
  • Health resource utilization in terms of length of ICU stay [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Length of intensive care unit (ICU) stay (days)
  • Health resource utilization in terms of transfer to ICU [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Transfer to the ICU (Yes/No)
  • Health resource utilization in terms of use of mechanical ventilation [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Mechanical ventilation (Yes/No) for HAP/VAP subjects
  • Health resource utilization in terms of duration of mechanical ventilation [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Length of mechanical ventilation (days) for HAP/VAP subjects
  • Health resource utilization in terms of subsequent unplanned surgical intervention [ Time Frame: Test of Cure (TOC), Day 28 +/- 3 days ]
    Subsequent unplanned surgical intervention (YES/NO) for cIAI subjects
 
Descriptive Information
Brief Title  ICMJE A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
Official Title  ICMJE A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS
Brief Summary A Phase 3 comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) versus Meropenem (MER) ± Colistin (COL) for the treatment of serious infections due to Gram negative bacteria.
Detailed Description A Phase 3 Prospective, Randomized, Multicenter, Open Label, Central Assessor Blinded, Parallel Group, Comparative Study To Determine The Efficacy, Safety And Tolerability Of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem±Colistin (MER±COL) For The Treatment Of Serious Infections Due To Gram Negative Bacteria, Including Metallo Β Lactamase (MBL) - Producing Multidrug Resistant Pathogens, For Which There Are Limited Or No Treatment Options
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Prospective, Randomized, Multicenter, Open Label, Central Assessor Blinded, Parallel Group, Comparative Study
Masking: Single (Outcomes Assessor)
Masking Description:

An independent adjudication committee (central blinded assessor) will be convened at regular intervals during the study. The adjudication committee will be blinded to study treatment and will review the clinical response assessments at each visit. In case of a discrepancy with the Investigator's assignment of clinical response, the adjudication committee's assessment will prevail.

In addition, for cIAI subjects classified as a clinical failure, and all cIAI subjects classified as a cure who undergo another procedure (eg, another surgical procedure) subsequent to randomization, the expert panel will review the adequacy of the surgical source control.

Primary Purpose: Treatment
Condition  ICMJE
  • Complicated Intra-abdominal Infection
  • Hosptial Acquired Pneumonia
  • Ventilator Associated Pneumonia
Intervention  ICMJE
  • Drug: ATM-AVI

    (Creatinine clearance > 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI

    (Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI

    (Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI

  • Drug: MTZ
    For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
  • Drug: MER

    Where pathogen initially not suspected of being MER-resistant:

    (Creatinine clearance > 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h

    (Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h

    (Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h

    Where pathogen initially suspected of being MER-resistant (Creatinine clearance > 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h

    (Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h

    (Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h

  • Drug: COL

    Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight < 60 kg) followed by one of the following maintenance doses:

    (Creatinine clearance > 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.

    (Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion

    (Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion

    (Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion

Study Arms  ICMJE
  • Experimental: Aztreonam-Avibactam ± Metronidazole
    All patients randomised to this arm will receive ATM-AVI; all patients with cIAI will receive MTZ for anaerobic cover
    Interventions:
    • Drug: ATM-AVI
    • Drug: MTZ
  • Active Comparator: Meropenem ± Colistin
    All patients randomised to this arm will receive MER; addition of COL will be at investigator's discretion in line with local practice
    Interventions:
    • Drug: MER
    • Drug: COL
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Suspended
Estimated Enrollment  ICMJE
 (submitted: July 31, 2018)
375
Original Estimated Enrollment  ICMJE
 (submitted: October 27, 2017)
300
Estimated Study Completion Date  ICMJE September 24, 2021
Estimated Primary Completion Date September 8, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

All subjects:

  1. Male or female from 18 years of age
  2. Provision of informed consent
  3. Confirmed diagnosis of HAP/VAP or cIAI requiring iv antibiotic treatment
  4. Female patients are authorized to participate in this clinical study if criteria concerning pregnancy avoidance stated in the protocol are met and negative pregnancy test

Additional for cIAI:

  1. Diagnosis of cIAI, EITHER:

    Intra-operative/postoperative enrolment with visual confirmation of cIAI. OR Preoperative enrollment with evidence of systemic inflammatory response, physical and radiological findings consistent with cIAI; confirmation of cIAI at time of surgery within 24 hours of study entry

  2. Surgical intervention within 24 hours (before or after) the administration of the first dose of study drug

Additional for HAP/VAP:

  1. Onset symptoms > 48h after admission to or <7 days after discharge from an inpatient care facility
  2. New or worsening infiltrate on CXR or CT scan
  3. Clinical signs and symptoms and laboratory findings consistent with HAP/VAP
  4. Respiratory specimen obtained for Gram stain and culture following onset of symptoms and prior to randomisation

Exclusion criteria:

All subjects:

  1. APACHE II score > 30
  2. Confirmed or suspected infection caused by Gram-negative species not expected to respond to study drug, or Gram-positive species
  3. Receipt of >24 hr systemic antibiotic within 48h prior to randomisation (exception in case of treatment failure)
  4. History of serious allergy, hypersensitivity (eg, anaphylaxis), or any serious reaction to aztreonam, carbapenem,monobactam or other β-lactam antibiotics, avibactam, nitroimidazoles or metronidazole, or any of the excipients of the study drugs
  5. Known Clostridium difficle associated diarrhoea
  6. Requirement for effective concomitant systemic antibacterials or antifungals
  7. Creatinine clearance ≤15 ml/min or requirement or expectation for renal replacement therapy
  8. Acute hepatitis, cirrhosis, acute hepatic failure, chronic hepatic failure
  9. Hepatic disease as indicated by AST or ALT >3 × ULN. Patients with AST and/or ALT up to 5 × ULN are eligible if acute and documented by the investigator as being directly related infectious process
  10. Patient has a total bilirubin >2 × ULN, unless isolated hyperbilirubinemia is directly related to infectious process or due to known Gilbert's disease
  11. ALP >3 × ULN. Patients with values >3 × ULN and <5 x ULN are eligible if acute and directly related to the infectious process being treated
  12. Absolute neutrophil count <500/mm3
  13. Pregnant or breastfeeding or if of child bearing potential, not using a medically accepted effective method of birth control.
  14. Any other condition that may confound the results of the study or pose additional risks to the subject
  15. Unlikely to comply with protocol
  16. History of epilepsy or seizure disorders excluding febrile seizures of childhood

Additional for cIAI

  1. Diagnosis of abdominal wall abscess; small bowel obstruction or ischemic bowel disease without perforation; traumatic bowel perforation with surgery within 12 hours of diagnosis; perforation of gastroduodenal ulcer with surgery < 24 hours of diagnosis primary etiology is not likely to be infectious
  2. Simple cholecystitis, gangrenous cholecystitis without rupture, simple appendicitis, acute suppurative cholangitis, infected necrotizing pancreatitis, pancreatic abscess
  3. Prior liver, pancreas or small-bowel transplant
  4. Staged abdominal repair (STAR), open abdomen technique or marsupialisation

Additional for HAP/VAP

  1. APACHE II score < 10
  2. Known or high likelihood of Gram-positive monomicrobial infection
  3. Lung abscess, pleural empyema, post-obstructive pneumonia
  4. Lung or heart transplant
  5. Myasthenia gravis
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Bulgaria,   Chile,   Croatia,   Czechia,   Hungary,   Israel,   Italy,   Korea, Republic of,   Mexico,   Peru,   Russian Federation,   South Africa,   Spain,   Taiwan,   Thailand,   Turkey,   Ukraine,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03329092
Other Study ID Numbers  ICMJE C3601002
D4910C00004 ( Other Identifier: Alias Study Number )
2017-002742-68 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE
  • Innovative Medicines Initiative (IMI) COMBACTE-CARE (EU)
  • Biomedical Advanced Research and Development Authority
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date June 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP